Remdesivir use might proceed in India as few choices in sight – Home Health Choices
New Delhi | Mumbai: Demand for Remdesivir is just not…Latest Updates
As per the outcomes that Glenmark introduced to the regulator, the research confirmed no superior medical outcomes with the addition of Umifenovir, it added.
This was the second medical research after the profitable Favipiravir monotherapy trial earlier this 12 months that led the corporate to receiving the Emergency Use Authorisation for Favipiravir, Glenmark stated.
“These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection,” Monika Tandon Senior VP & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals stated. AKT BAL BAL